

ASX Release

Anatara Strengthens Board and Executive Team

Highlights

- **Dr Paul Schober appointed Chief Executive Officer (CEO)**
- **Mr Damian Wilson appointed Head of Global Business Development**
- **Mr Paul Grujic appointed Non-Executive Director**

BRISBANE, 24th February 2015: Animal Health and Human therapeutic company Anatara Lifesciences (ASX: ANR) is pleased to announce the appointment of two new members to its executive management team, and strengthens the board with a new non-executive director.

The board has appointed Dr Paul Schober as CEO, effective 2nd March 2015. Dr Schober leaves his position as General Manager for the Peptech Animal Health Division of global animal health company Virbac. He has extensive global experience in the animal health field encompassing R&D, clinical trial management, regulatory, manufacturing, sales and marketing as well as ASX investor relations.

Dr Schober's achievements include:

- First Australian biotechnology product to achieve FDA registration (Animal Health product, Ovuplant in 1998)
- Launch of Ovuplant in the US & the EU
- Regulatory approval and launch of animal health product Suprelorin in Australia and the EU
- Worldwide distribution agreements with leading animal health companies
- Successful positioning and trade sale of an animal health company

With Dr Schober's appointment, the current UK-based Managing Director Dr David Venables will retire as a director and continue on a contractual consultancy basis. Dr Venables will continue to play a key role in Anatara's global strategic positioning, manufacturing planning and play a pivotal role in the company's European (EU) regulatory plans.

Dr Schober said, "I am excited to be joining Anatara and look forward to working closely with the team to build a profitable global animal health business. The company has enormous potential to emerge as a new player in the animal health market."

Dr Venables played a key role in the formation of Anatara as a private company and successfully led the first private capital raising in early 2014 which then led to a further raising of \$7 million in the capital markets and a successful listing on the ASX in October the same year. David remains a significant shareholder in the company.



Dr Venables said, “It has been a privilege to play a key role in seeing Anatara grow from a start-up to now being an ASX listed company. It is my intention to continue to work closely with the company, particularly assisting with its plans to launch into the key Northern Hemisphere markets. This is an area where I have significant expertise.”

Anatara’s business development capability has been boosted with the appointment of Mr Damian Wilson as the Head of Global Business Development. Mr Wilson has extensive international experience in both Australian and international based animal health companies, including start-up enterprises as well as large private companies. He has a proven track record in managing, business development, partnering, and sales and marketing of animal health products across more than 20 countries, including entry into new Asian markets. Mr Wilson has occupied senior positions at large agribusiness companies including Norbrook Laboratories and Coopers Animal Health.

Mr Wilson said that joining Anatara offered immense opportunities in growing a successful animal health franchise.

“The company has a valuable lead product in Detach™ followed by a potentially deep pipeline of further animal health and human naturally based therapeutic products,” he said.

The board has been further strengthened by the appointment of Paul Grujic as a non-executive director. Mr Grujic was most recently the President of CSL Animal Health and a member of CSL’s Executive Committee and was responsible for CSL’s global animal health business with a staff of 250 and three manufacturing sites in Australia, the USA and New Zealand. He has also held senior positions in a number of global companies including Glaxo, Fort Dodge, American Cynamid, Pitman-Moore and Webster Animal Health.

Mr Grujic also played leading roles in the sale of Catapult Genetics and CSL’s Animal Health business to global pharmaceutical company Pfizer. He was also involved in the sale of Peptech Animal Health to leading international animal health company Virbac.

Mr Grujic said, “I am excited to be joining the Anatara Board and working with a dedicated team to grow the company into a very successful listed company. I am impressed with the potential the Anatara product pipeline and technology offers.”

Chairman Dr Mel Bridges said, “Our ability to attract such high caliber appointments is a strong testimony of the potential of Anatara. We have now built a strong team, with a proven track record in executing and delivering. This team is an important asset as we progress the development of Detach™ and maintain our focus on delivering superior shareholder returns.

“On behalf of the board I want to express my gratitude for David Venable’s commitment to positioning Anatara as an ASX listed company, and we look forward to working closely with David into the future as we open up new markets.”

For more information please contact:

General inquiries

Mel Bridges

Chairman

+61 (0) 413 051 600

melbridges@parmacorp.com

Media inquiries

Gavin Lower

Buchan Consulting

+61 3 8866 1215

glower@buchanwe.com.au

About Anataro Lifesciences

Anataro Lifesciences (ASX: ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural, plant based product that will help address global concern about the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anataro team has a strong track record in biological science as well as building and growing international biotech companies. For more information visit www.anatarolifesciences.com.

For personal use only